Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.57 |
| ▸ | YAP1 | P46937 | 1/20 | 0.57 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 4/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | DLK1 | P80370 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22718294 | 0.88 | TEAD1 (0.74) | TEAD1YAP1TLR2TLR1MAPT | |
| SCHEMBL29438829 | 0.88 | TEAD1 (0.74) | TEAD1YAP1TLR2TLR1MAPT | |
| SCHEMBL22718252 | 0.87 | TEAD1 (0.59) | TEAD1YAP1TLR2TLR1MAPT | |
| SCHEMBL22843443 | 0.84 | TEAD1 (0.40) | TEAD1YAP1TLR2TLR1MAPT | |
| SCHEMBL22718177 | 0.84 | TEAD1 (0.55) | TEAD1YAP1TLR2TLR1MAPT | |
| SCHEMBL29438840 | 0.81 | TEAD1 (0.59) | TEAD1YAP1TLR2TLR1TAS2R14 | |
| SCHEMBL22718083 | 0.81 | TEAD1 (0.59) | TEAD1YAP1TLR2TLR1TAS2R14 | |
| SCHEMBL22718145 | 0.80 | BMP1 (0.38) | TEAD1YAP1TLR2TLR1IDH2 | |
| SCHEMBL22718260 | 0.78 | TEAD1 (0.59) | TEAD1YAP1TLR2TLR1MAPT | |
| SCHEMBL29438857 | 0.78 | TEAD1 (0.59) | TEAD1YAP1TLR2TLR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| CN-119954725-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114466839-B | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2024-03-14 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2022187518-A1 | SUBSTITUTED 4-PIPERIDINYL-IMIDAZO[4,5-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220251048-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2022-08-11 | — | — | US | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-3976194-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251048-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885TLR2 4827/4885 |
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885TLR2 4827/4885 |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885TLR2 4827/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885TLR2 4827/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | TEAD1 7/4885YAP1 13/4885TLR2 4676/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885TLR2 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.